白细胞计数与头孢吡肟对比哌拉西林-他唑巴坦治疗反应的关联
该研究对 ACORN 随机试验和一项工具变量研究进行事后亚组分析,探讨白细胞计数是否修饰头孢吡肟与哌拉西林-他唑巴坦对 28 天死亡率的影响。ACORN 试验和工具变量研究均发现白细胞计数与治疗组存在显著交互作用(OR 0.95 [95%CI 0.92-0.98],P<.01;OR 0.95 [95%CI 0.94-0.96],P<.01)。在 ACORN 队列中,基线白细胞计数≥16 的患者使用哌拉西林-他唑巴坦相比头孢吡肟的死亡比值显著更低(OR 0.51 [95%CI 0.29-0.90])。作者认为白细胞计数修饰了抗生素选择对死亡率的影响,需进一步前瞻性研究确认,并探讨白细胞计数能否用于未来抗假单胞菌抗生素试验的预测性富集。
要点
- ACORN 试验事后分析:基线白细胞计数≥16 的患者,哌拉西林-他唑巴坦组相比头孢吡肟组 28 天死亡比值更低(OR 0.51 [95%CI 0.29-0.90])。
- ACORN 试验和工具变量研究均显示白细胞计数与治疗组对 28 天死亡率存在显著交互作用(OR 0.95 [95%CI 0.92-0.98],P<.01;OR 0.95 [95%CI 0.94-0.96],P<.01)。
- 似然比检验显示纳入交互项后模型拟合更优(F=8.17,P≤.01;F=42.9,P<.01)。
- 作者结论:白细胞计数修饰了抗生素选择对死亡率的影响,需前瞻性研究确认,并探讨其用于未来试验预测性富集的可能性。
适用人群与场景
- ACORN 随机试验与工具变量研究的事后亚组分析人群,比较头孢吡肟与哌拉西林-他唑巴坦的经验性抗假单胞菌治疗。
研究设计与关键结果
- 研究类型:ACORN 随机试验和工具变量研究的事后亚组分析;主要终点为 28 天死亡率。
- ACORN 试验中白细胞计数与治疗组对 28 天死亡率存在显著交互作用(OR 0.95 [95%CI 0.92-0.98],P<.01),似然比检验 F=8.17,P≤.01。
- 工具变量研究中白细胞计数与治疗组对 28 天死亡率存在显著交互作用(OR 0.95 [95%CI 0.94-0.96],P<.01),似然比检验 F=42.9,P<.01。
- ACORN 队列中基线白细胞计数≥16 的患者,哌拉西林-他唑巴坦组相比头孢吡肟组 28 天死亡比值显著更低(OR 0.51 [95%CI 0.29-0.90])。
- ACORN 试验二次分析次要结局包括:急性肾损伤最高分期(序数量表)、主要不良肾脏事件复合结局、14 天内昏迷或谵妄发生率。
证据类型、等级与局限
- 证据类型:随机对照试验(ACORN)和工具变量研究的事后亚组分析。
- 局限:原文报告需进一步前瞻性研究确认该效应,并确定白细胞计数能否用于未来抗假单胞菌抗生素试验的预测性富集。
对床旁实践的改变
- 作者认为白细胞计数修饰了抗生素选择对死亡率的影响,需前瞻性研究确认,并探讨白细胞计数能否用于未来抗假单胞菌抗生素试验的预测性富集。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
RATIONALE: Empiric anti-pseudomonal coverage is an important part of treatment of sepsis, but there are limited data to guide antibiotic selection. The Antibiotic Choice on Renal Outcomes (ACORN) randomized trial found no difference in mortality when comparing cefepime and piperacillin-tazobactam, while an instrumental variable (IV) study found improved mortality with cefepime.
OBJECTIVES: To determine if white blood cell (WBC) count modifies the effect of antibiotic choice on mortality.
METHODS: We conducted post hoc subgroup analyses of the ACORN trial and the IV study comparing cefepime to piperacillin-tazobactam. We performed regression modeling of interaction between treatment group and WBC on 28-day mortality with adjustment for relevant covariates, with evaluation for heterogeneity of treatment effect through likelihood ratio testing.
MEASUREMENTS AND MAIN RESULTS: The main outcome was 28-day mortality in both cohorts. Secondary outcomes in the secondary analysis of the ACORN trial included highest stage of acute kidney injury on an ordinal scale, a composite outcome of major adverse kidney events, and incidence of coma or delirium within 14 days. There was a significant interaction between WBC and treatment group in predicting 28-day mortality in both the ACORN trial and the IV study (odds ratio [OR], 0.95 [95% CI, 0.92-0.98], P <.01 and OR, 0.95 [95% CI, 0.94-0.96], P <.01, respectively), with likelihood ratio testing revealing better model fit with inclusion of the interaction term (F = 8.17, P =<.01 and F = 42.9, P <.01, respectively). In the ACORN cohort, patients with a baseline WBC count of 16 or higher had significantly lower odds of mortality when treated with piperacillin-tazobactam compared to cefepime (OR, 0.51 [95% CI, 0.29-0.90]).
CONCLUSIONS: WBC modified the effect of antibiotic choice on mortality in 2 large clinical studies. Further research is needed to confirm this effect in prospective studies and to determine if WBC count could be used for predictive enrichment in future trials of anti-pseudomonal antibiotics.
参考来源
- Rzewnicki DI, Chanderraj R, Qian ET, et al. Association of white blood cell count with treatment response to cefepime versus piperacillin-tazobactam. Am J Respir Crit Care Med. 2026. PMID: 42275170. doi:10.1093/ajrccm/aamag257
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。